Virtus Investment Advisers LLC Sells 43,446 Shares of Sana Biotechnology, Inc. $SANA

Virtus Investment Advisers LLC lowered its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 54.0% in the second quarter, Holdings Channel reports. The institutional investor owned 37,021 shares of the company’s stock after selling 43,446 shares during the period. Virtus Investment Advisers LLC’s holdings in Sana Biotechnology were worth $101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Invesco Ltd. raised its holdings in Sana Biotechnology by 241.5% in the first quarter. Invesco Ltd. now owns 165,646 shares of the company’s stock worth $278,000 after purchasing an additional 117,144 shares in the last quarter. SCS Capital Management LLC purchased a new position in shares of Sana Biotechnology in the 1st quarter worth approximately $137,000. CWM LLC grew its position in shares of Sana Biotechnology by 125.7% in the 2nd quarter. CWM LLC now owns 86,750 shares of the company’s stock worth $237,000 after buying an additional 48,319 shares during the last quarter. Ieq Capital LLC raised its stake in shares of Sana Biotechnology by 428.7% during the 1st quarter. Ieq Capital LLC now owns 104,832 shares of the company’s stock worth $176,000 after acquiring an additional 85,004 shares in the last quarter. Finally, Clearline Capital LP purchased a new stake in Sana Biotechnology during the first quarter valued at approximately $690,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SANA has been the topic of several recent analyst reports. Citizens Jmp upped their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. JMP Securities set a $8.00 price target on Sana Biotechnology in a research note on Thursday, October 30th. HC Wainwright cut their price objective on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Wednesday, October 8th. Finally, Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.33.

Sana Biotechnology Stock Up 10.1%

Shares of NASDAQ SANA opened at $4.43 on Friday. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -4.56 and a beta of 1.94. The company’s 50-day simple moving average is $4.27 and its 200-day simple moving average is $3.56. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. Equities research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.